Literature DB >> 22575642

The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II.

Inken Lorenzen1, Juliane Lokau, Stefan Düsterhöft, Ahmad Trad, Christoph Garbers, Jürgen Scheller, Stefan Rose-John, Joachim Grötzinger.   

Abstract

A great number of physiological processes are regulated by the release of ectodomains of membrane proteins. A Disintegrin And Metalloprotease 17 (ADAM17) is one of the important enzymes, which mediate this process called shedding. Today, more than 70 substrates of this transmembrane metalloprotease are known. This broad spectrum raises the question how ADAM17 recognizes its substrates specifically. Differently tagged ADAM17 deletion variants were used to demonstrate that exclusively the extracellular domains of ADAM17 are needed for interaction with two of its substrates, the IL-6R and the IL-1RII; whereas the transmembrane- and cytoplasmic-region are dispensable for this process. In the extracellular part solely the membrane-proximal domain of ADAM17 is mandatory for recognition of the two type-I transmembrane proteins, but not for the interaction with the type-II transmembrane molecule TNF-α.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575642     DOI: 10.1016/j.febslet.2012.03.012

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  25 in total

Review 1.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

2.  A Disintegrin and Metalloproteinase 17 is required for ILC2 responses to IL-33.

Authors:  Joseph C Lownik; Daniel H Conrad; Rebecca K Martin
Journal:  Biochem Biophys Res Commun       Date:  2019-03-27       Impact factor: 3.575

3.  IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.

Authors:  Fella Tamzalit; Isabelle Barbieux; Ariane Plet; Julie Heim; Steven Nedellec; Sébastien Morisseau; Yannick Jacques; Erwan Mortier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

4.  Circulating ADAM17 Level Reflects Disease Activity in Proteinase-3 ANCA-Associated Vasculitis.

Authors:  Anna Bertram; Svjetlana Lovric; Alissa Engel; Michaela Beese; Kristin Wyss; Barbara Hertel; Joon-Keun Park; Jan U Becker; Johanna Kegel; Hermann Haller; Marion Haubitz; Torsten Kirsch
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

5.  Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor α ectodomain shedding.

Authors:  Jeanette Schwarz; Stefanie Schmidt; Olga Will; Tomas Koudelka; Kaja Köhler; Melanie Boss; Björn Rabe; Andreas Tholey; Jürgen Scheller; Dirk Schmidt-Arras; Michael Schwake; Stefan Rose-John; Athena Chalaris
Journal:  J Biol Chem       Date:  2013-12-13       Impact factor: 5.157

6.  A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor.

Authors:  Stefan Düsterhöft; Katharina Höbel; Mirja Oldefest; Juliane Lokau; Georg H Waetzig; Athena Chalaris; Christoph Garbers; Jürgen Scheller; Stefan Rose-John; Inken Lorenzen; Joachim Grötzinger
Journal:  J Biol Chem       Date:  2014-04-30       Impact factor: 5.157

7.  Differential expression of transcription factors and inflammation-, ROS-, and cell death-related genes in organotypic cultures in the modiolus, the organ of Corti and the stria vascularis of newborn rats.

Authors:  Johann Gross; Heidi Olze; Birgit Mazurek
Journal:  Cell Mol Neurobiol       Date:  2014-03-05       Impact factor: 5.046

8.  Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.

Authors:  Paul Baran; Rebecca Nitz; Joachim Grötzinger; Jürgen Scheller; Christoph Garbers
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

Review 9.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

Review 10.  Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.

Authors:  Martina Molgora; Domenico Supino; Alberto Mantovani; Cecilia Garlanda
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.